Minerva Surgical Inc (UTRS) Fair Value & Analysis
Healthcare · US · Market cap $887
Minerva Surgical Inc
UTRS · US
Fair value as of: Jul 31, 2026
From 1 valuation models · updated 18 days ago
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.
How to read this chart
58‑month range $0.0001 – $195.60 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Jul 31, 2026.
Analysis
Minerva Surgical Inc (UTRS) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Over the trailing twelve months, Minerva Surgical Inc generated revenue of $51.7M at a net margin of -64.7%. Revenue declined 4.9% year over year. Net debt stands at $32.7M. Fundamentals as of Jul 31, 2026
For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at 0%, UTRS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when UTRS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 28 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Minerva Surgical, Inc. provides a suite of devices to treat the root causes of abnormal uterine bleeding in the United States.
Full company description
Minerva Surgical, Inc. provides a suite of devices to treat the root causes of abnormal uterine bleeding in the United States. The company provides Minerva Endometrial Ablation System, a technology that uses three methods of tissue ablation; Symphion System that is designed for fluid management, direct intrauterine pressure monitoring, and bladeless resection work; and Genesys HTA, an endometrial ablation device for the treatment of a wider range of uterine cavities. It also offers Resectr, a tissue resection device to diagnose and treat polyps; and HERizon electronic disposable hysteroscope, image processor, Hysto-Kit, and endoscopic accessories that helps gynecologists to evaluate abnormal uterine bleeding and provide care. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2019 – FY2023 · reported fiscal years
Minerva Surgical Inc reported revenue of $51.7M in FY2023 versus $26.0M in FY2019, a compound +18.7%/yr. Reported net income was −$33.5M in FY2023.
Watch UTRS: get an alert when its fair value changes →
Peer Group
Medical Devices · 353 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $110.91 | $74.79 | -33% |
| Stryker Corporation SYK | $347.21 | $186.28 | -46% |
| Medtronic plc MDT | $90.76 | $65.57 | -28% |
| Boston Scientific Corporation BSX | $51.42 | $38.44 | -25% |
| Edwards Lifesciences Corporation EW | $93.05 | $41.02 | -56% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥153.60 | ¥147.63 | -4% |
| Shanghai United Imaging Healthcare Co 688271 | ¥110.50 | ¥43.60 | -61% |
| Demant A/S DEMANT | kr 289.60 | kr 161.17 | -44% |
| Getinge AB GETIB | kr 239.30 | kr 192.14 | -20% |
| Sectra AB SECTB | kr 280.00 | kr 66.81 | -76% |
Compare Minerva Surgical Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Minerva Surgical Inc (UTRS) overvalued or undervalued?
What is the fair value of UTRS?
What is the quality score of UTRS?
What is the revenue of Minerva Surgical Inc (UTRS)?
What is the net profit margin of UTRS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Minerva Surgical Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.